



## Complete Summary

---

### GUIDELINE TITLE

Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department.

### BIBLIOGRAPHIC SOURCE(S)

Lukens TW, Wolf SJ, Edlow JA, Shahabuddin S, Allen MH, Currier GW, Jagoda AS, ACEP Clinical Policies Subcommittee (Writing Committee) on Critical Issues [trunc]. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. *Ann Emerg Med* 2006 Jan;47(1):79-99. [65 references] [PubMed](#)

### GUIDELINE STATUS

This is the current release of the guideline.

## \*\* REGULATORY ALERT \*\*

### FDA WARNING/REGULATORY ALERT

**Note from the National Guideline Clearinghouse:** This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

- [September 17, 2007, Haloperidol \(Haldol\)](#): Johnson and Johnson and the U.S. Food and Drug Administration (FDA) informed healthcare professionals that the WARNINGS section of the prescribing information for haloperidol has been revised to include a new Cardiovascular subsection.
- [April 12, 2005, Atypical Antipsychotic Drugs](#): Public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved, "off-label" use of certain antipsychotic drugs approved for the treatment of schizophrenia and mania.

## COMPLETE SUMMARY CONTENT

\*\* REGULATORY ALERT \*\*

SCOPE

METHODOLOGY - including Rating Scheme and Cost Analysis

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

QUALIFYING STATEMENTS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT

## SCOPE

### **DISEASE/CONDITION(S)**

Behavioral emergencies from acute psychotic disturbances, manic episodes, major depression, bipolar disorder, and substance abuse

### **GUIDELINE CATEGORY**

Diagnosis  
Evaluation  
Management  
Screening  
Treatment

### **CLINICAL SPECIALTY**

Emergency Medicine  
Psychiatry

### **INTENDED USERS**

Physicians

### **GUIDELINE OBJECTIVE(S)**

- To provide evidence-based recommendations for the medical assessment and management of adult patients who present to the emergency department (ED) with psychiatric symptoms
- To address the following critical questions:
  - What testing is necessary in order to determine medical stability in alert, cooperative patients with normal vital signs, a noncontributory history and physical examination, and psychiatric symptoms?
  - Do the results of a urine drug screen for drugs of abuse affect management in alert, cooperative patients with normal vital signs, a noncontributory history and physical examination, and a psychiatric complaint?
  - Does an elevated alcohol level preclude the initiation of a psychiatric evaluation in alert, cooperative patients with normal vital signs and a noncontributory history and physical examination?
  - What is the most effective pharmacologic treatment for the acutely agitated patient in the ED?

### **TARGET POPULATION**

Adult patients presenting to the emergency department with psychiatric symptoms

This guideline, with the exception of question IV (see the "Major Recommendations" field), is not intended for patients with delirium or abnormal vital signs, altered cognition, or abnormal physical examination. Pediatric patients are also excluded.

## **INTERVENTIONS AND PRACTICES CONSIDERED**

### **Diagnosis/Evaluation**

1. Routine laboratory evaluation in emergency department psychiatric patients with normal vital signs and a noncontributory history and physical examination.
2. Urine toxicologic screens for drugs of abuse in the evaluation of alert, cooperative psychiatric patients with normal vital signs and a noncontributory history and physical examination in the emergency department.
3. Blood alcohol testing in patients being evaluated for psychiatric conditions in the emergency department.

### **Treatment**

1. Pharmacologic treatment of acute agitation in the emergency department setting with benzodiazepines and/or antipsychotics.

## **MAJOR OUTCOMES CONSIDERED**

- Utility and effectiveness of routine laboratory testing, urine screens for drugs of abuse, and blood alcohol testing in the assessment of emergency department patients with psychiatric complaints
- Efficacy of various pharmacologic treatments of the agitated patient in the emergency department

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Hand-searches of Published Literature (Primary Sources)  
Hand-searches of Published Literature (Secondary Sources)  
Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

MEDLINE searches for articles published between January 1980 and January 2005 were performed using a combination of key words and their variations, including "psychiatry," "medical clearance," "agitation," "toxicologic screens," "drugs of abuse," "alcohol testing," and names of individual drugs. Searches were limited to English-language sources. Additional articles were reviewed from the bibliography of articles cited. Subcommittee members also supplied articles from their own knowledge base.

### **NUMBER OF SOURCE DOCUMENTS**

Not stated

## **METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Weighting According to a Rating Scheme (Scheme Given)

### **RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE**

**Strength of evidence Class I**--Interventional studies including clinical trials, observational studies including prospective cohort studies, aggregate studies including meta-analyses of randomized clinical trials only

**Strength of evidence Class II**--Observational studies including retrospective cohort studies, case-controlled studies, aggregate studies including other meta-analyses

**Strength of evidence Class III**--Descriptive cross-sectional studies, observational reports including case series and case reports, consensus studies including published panel consensus by acknowledged groups of experts

Strength of evidence Class I and II articles were then rated on elements subcommittee members believed were most important in creating a quality work. Class I and II articles with significant flaws or design bias were downgraded on the basis of a set formula (see Appendix C in the original guideline document). Strength of evidence Class III articles were downgraded if they demonstrated significant flaws or bias. Articles downgraded below strength of evidence Class III were given an "X" rating and were not used in formulating recommendations in this policy.

### **METHODS USED TO ANALYZE THE EVIDENCE**

Systematic Review with Evidence Tables

### **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

This clinical policy was created after careful review and critical analysis of the medical literature.

All publications were graded by at least 2 of the subcommittee members into 1 of 3 categories of strength of evidence. Some articles were downgraded on the basis of a standardized formula that considers the size of study population, methodology, validity of conclusions, and potential sources of bias (see Appendix B of the original guideline document).

During the review process, all articles were given a baseline "strength of evidence" by the subcommittee members according to the criteria outlined in "Rating Scheme for the Strength of the Evidence."

An Evidentiary Table was constructed and is included in the original guideline document.

## **METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Expert Consensus

## **DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS**

This policy is a product of the American College of Emergency Physicians (ACEP) clinical policy development process and is based on the existing literature; where literature was not available, consensus of emergency and psychiatric physicians was used.

## **RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

Recommendations regarding patient management were made according to the following criteria:

### **Strength of Recommendations**

**Level A recommendations.** Generally accepted principles for patient management that reflect a high degree of clinical certainty (i.e., based on "strength of evidence Class I" or overwhelming evidence from "strength of evidence Class II" studies that directly address all the issues)

**Level B recommendations.** Recommendations for patient management that may identify a particular strategy or range of management strategies that reflect moderate clinical certainty (i.e., based on "strength of evidence Class II" studies that directly address the issue, decision analysis that directly addresses the issue, or strong consensus of "strength of evidence Class III" studies)

**Level C recommendations.** Other strategies for patient management based on preliminary, inconclusive, or conflicting evidence, or, in the absence of any published literature, based on panel consensus

There are certain circumstances in which the recommendations stemming from a body of evidence should not be rated as highly as the individual studies on which they are based. Factors such as heterogeneity of results, uncertainty about effect magnitude and consequences, strength of prior beliefs, and publication bias, among others, might lead to such a downgrading of recommendations.

## **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

## **METHOD OF GUIDELINE VALIDATION**

External Peer Review  
Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Expert review comments were received from individual emergency physicians and psychiatrists and from members of the American Association for Emergency Psychiatry, American Association of Community Psychiatrists, American Psychiatric Association, and Emergency Nurses Association. Their responses were used to further refine and enhance this policy.

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

Definitions for the strength of evidence (Class I-III) and strength of recommendations (Level A-C) are repeated at the end of the "Major Recommendations" field.

1. **What testing is necessary in order to determine medical stability in alert, cooperative patients with normal vital signs, a noncontributory history and physical examination, and psychiatric symptoms?**

**Level A recommendations.** None specified.

**Level B recommendations.** In adult emergency department (ED) patients with primary psychiatric complaints, diagnostic evaluation should be directed by the history and physical examination. Routine laboratory testing of all patients is of very low yield and need not be performed as part of the ED assessment.

**Level C recommendations.** None specified.

2. **Do the results of a urine drug screen for drugs of abuse affect management in alert, cooperative patients with normal vital signs, a noncontributory history and physical examination, and a psychiatric complaint?**

**Level A recommendations.** None specified.

**Level B recommendations.** None specified.

**Level C recommendations.**

1. Routine urine toxicologic screens for drugs of abuse in alert, awake, cooperative patients do not affect ED management and need not be performed as part of the ED assessment.
2. Urine toxicologic screens for drugs of abuse obtained in the ED for the use of the receiving psychiatric facility or service should not delay patient evaluation or transfer.

3. **Does an elevated alcohol level preclude the initiation of a psychiatric evaluation in alert, cooperative patients with normal vital signs and a noncontributory history and physical examination?**

**Level A recommendations.** None specified.

**Level B recommendations.** None specified.

**Level C recommendations.**

1. The patient's cognitive abilities, rather than a specific blood alcohol level, should be the basis on which clinicians begin the psychiatric assessment.
  2. Consider using a period of observation to determine if psychiatric symptoms resolve as the episode of intoxication resolves.
4. **What is the most effective pharmacologic treatment for the acutely agitated patient in the ED?**

**Level A recommendations.** None specified.

**Level B recommendations.**

1. Use a benzodiazepine (lorazepam or midazolam) or a conventional antipsychotic (droperidol\* or haloperidol) as effective monotherapy for the initial drug treatment of the acutely agitated undifferentiated patient in the ED.
2. If rapid sedation is required, consider droperidol\* instead of haloperidol.
3. Use an antipsychotic (typical or atypical) as effective monotherapy for both management of agitation and initial drug therapy for the patient with known psychiatric illness for which antipsychotics are indicated.
4. Use a combination of an oral benzodiazepine (lorazepam) and an oral antipsychotic (risperidone) for agitated but cooperative patients.

**Level C recommendations.** The combination of a parenteral benzodiazepine and haloperidol may produce more rapid sedation than monotherapy in the acutely agitated psychiatric patient in the ED.

\*Refer to the discussion of droperidol in the original guideline document.

### **Definitions:**

#### **Strength of Evidence**

**Strength of evidence Class I**--Interventional studies including clinical trials, observational studies including prospective cohort studies, aggregate studies including meta-analyses of randomized clinical trials only

**Strength of evidence Class II**--Observational studies including retrospective cohort studies, case-controlled studies, aggregate studies including other meta-analyses

**Strength of evidence Class III**--Descriptive cross-sectional studies, observational reports including case series and case reports, consensus studies including published panel consensus by acknowledged groups of experts

### **Strength of Recommendations**

**Level A recommendations.** Generally accepted principles for patient management that reflect a high degree of clinical certainty (i.e., based on "strength of evidence Class I" or overwhelming evidence from "strength of evidence Class II" studies that directly address all the issues)

**Level B recommendations.** Recommendations for patient management that may identify a particular strategy or range of management strategies that reflect moderate clinical certainty (i.e., based on "strength of evidence Class II" studies that directly address the issue, decision analysis that directly addresses the issue, or strong consensus of "strength of evidence Class III" studies)

**Level C recommendations.** Other strategies for patient management based on preliminary, inconclusive, or conflicting evidence, or, in the absence of any published literature, based on panel consensus

There are certain circumstances in which the recommendations stemming from a body of evidence should not be rated as highly as the individual studies on which they are based. Factors such as heterogeneity of results, uncertainty about effect magnitude and consequences, strength of prior beliefs, and publication bias, among others, might lead to such a downgrading of recommendations.

### **CLINICAL ALGORITHM(S)**

None provided

## **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

## **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

### **POTENTIAL BENEFITS**

Appropriate evaluation and management of patients with psychiatric symptoms

### **POTENTIAL HARMS**

#### **Adverse Effects of Medications**

- Caution needs to be taken in caring for agitated patients with medical illness so that any reversible causes are identified and treated. In addition, agitation

may be a result of drug ingestions or poisonings with anticholinergic or sympathomimetic agents. In this scenario, the antipsychotics, both conventional and atypical, and the medications used to manage extrapyramidal symptoms can potentially exacerbate agitation because of their anticholinergic side effects.

- In 2001, the US Food and Drug Administration (FDA) issued a black box warning about *droperidol's* potential for dysrhythmias, making its subsequent use problematic. However, large patient series have appeared attesting to its safety. Some authors have reviewed the existing reports of droperidol toxicity, including all of the material submitted to the FDA on which the ruling was based, and concluded that although droperidol can be associated with prolongation of the QT interval, there is not convincing evidence that the drug causes severe cardiac events.
- Atypical and conventional antipsychotics can cause QTc interval prolongation and dystonia.

## QUALIFYING STATEMENTS

### QUALIFYING STATEMENTS

Recommendations offered in this policy are not intended to represent the only diagnostic and management options that the emergency physician should consider. The American College of Emergency Physicians (ACEP) clearly recognizes the importance of the individual physician's judgment. Rather, this guideline defines for the physician those strategies for which medical literature exists to provide support for answers to the crucial questions addressed in this policy.

## IMPLEMENTATION OF THE GUIDELINE

### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better

### IOM DOMAIN

Effectiveness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Lukens TW, Wolf SJ, Edlow JA, Shahabuddin S, Allen MH, Currier GW, Jagoda AS, ACEP Clinical Policies Subcommittee (Writing Committee) on Critical Issues [trunc]. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. *Ann Emerg Med* 2006 Jan;47(1):79-99. [65 references] [PubMed](#)

## **ADAPTATION**

Not applicable: The guideline was not adapted from another source.

## **DATE RELEASED**

2006 Jan

## **GUIDELINE DEVELOPER(S)**

American College of Emergency Physicians - Medical Specialty Society

## **SOURCE(S) OF FUNDING**

American College of Emergency Physicians

## **GUIDELINE COMMITTEE**

Clinical Policies Subcommittee on Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department

ACEP Clinical Policies Committee

## **COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

*Clinical Policies Subcommittee (Writing Committee) on Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department Members:* Thomas W. Lukens, MD, PhD, (Chair); Stephen J. Wolf, MD; Jonathan A. Edlow, MD; Samina Shahabuddin, MD; Michael H. Allen, MD, (American Association for Emergency Psychiatry); Glenn W. Currier, MD, MPH, (American Association for Emergency Psychiatry); Andy S. Jagoda, MD, (Chair, Clinical Policies Committee)

*American College of Emergency Physicians (ACEP) Clinical Policies Committee (Oversight Committee) Members:* William C. Dalsey, MD (Chair, 2000-2002, Co-Chair 2002-2003); Andy S. Jagoda, MD (Co-Chair 2002-2003, Chair, 2003-2006); Wyatt W. Decker, MD; Jonathan A. Edlow, MD; Francis M. Fesmire, MD; Steven A. Godwin, MD; Sigrid A. Hahn, MD (EMRA Representative 2003-2004); John M. Howell, MD; Shkelzen Hoxhaj, MD (EMRA Representative 2002-2003); J. Stephen Huff, MD; Edwin K. Kuffner, MD; JoAnn Lazarus, RN, MSN, CEN (ENA Representative 2003); Thomas W. Lukens, MD, PhD; Benjamin E. Marett, RN, MSN, CEN, CNA, COHN-S (ENA Representative 2002); Donna L. Mason, RN, MS, CEN (ENA Representative 2005); Michael Moon, RN, CNS, MSN, CEN (ENA Representative 2004); Anthony M. Napoli, MD (EMRA Representative 2004-2006); Devorah Nazarian, MD; Scott M. Silvers, MD; Edward P. Sloan, MD, MPH; Robert

L. Wears, MD, MS (Methodologist); Stephen J. Wolf, MD (EMRA Representative 2001-2002, committee member 2003-2006); John T. Finnell, II, MD, MSc (Liaison Member for Emergency Medical Informatics Section); Susan M. Nedza, MD, MBA (Board Liaison 2001-2003); John Skiendzielewski, MD (Board Liaison 2003-2004); Cherri D. Hobgood, MD (Board Liaison 2004-2006); Rhonda R. Whitson, RHIA, Staff Liaison, Clinical Policies Committee and Subcommittees

## **FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST**

Not stated

## **ENDORSER(S)**

American Association for Emergency Psychiatry - Medical Specialty Society

## **GUIDELINE STATUS**

This is the current release of the guideline.

## **GUIDELINE AVAILABILITY**

Electronic copies: Available in Portable Document Format (PDF) from the [American College of Emergency Physicians Web site](#).

Print copies: Available from the American College of Emergency Physicians, P.O. Box 619911, Dallas, TX 75261-9911, or call toll free: (800) 798-1822.

## **AVAILABILITY OF COMPANION DOCUMENTS**

None available

## **PATIENT RESOURCES**

None available

## **NGC STATUS**

This NGC summary was completed by ECRI on February 13, 2006. The information was verified by the guideline developer on April 6, 2006. This summary was updated by ECRI Institute on October 2, 2007, following the U.S. Food and Drug Administration (FDA) advisory on Haloperidol.

## **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. For more information, please refer to the [American College of Emergency Physicians \(ACEP\) Web site](#).

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 11/3/2008

